CD33 and acute myeloid leukemia: Currently, there are 75 registered clinical trials of CAR-T cell therapy for AML (Table 2), of which 53 (71%) are Phase 1 or early Phase 1 trials, with CD33 and CD123 being the most frequently targeted antigens (Fig. 4).